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18.1  DNA REPAIR IN CANCER
Cells are under constant genotoxic pressure from both endogenous and exogenous 
sources. It has been estimated that every day a single human cell has to endure 
tens of thousands of DNA lesions (Jackson and Bartek 2009). This damage needs 
to be repaired to avoid detrimental mutations, blockage of replication and tran-
scription, and chromosomal breakage. DNA repair is the collection of the multiple 
and diverse ways through which living cells identify alterations in the chemistry 
of their DNA molecules and correct the damage to restore the integrity of their 
genome. In cancer, DNA repair serves as a significant barrier that can prevent pre-
neoplastic cells from progressing through malignant transformation. The impor-
tance of DNA repair in preventing cancer was first demonstrated in the study of 
patients with xeroderma pigmentosum (XP), a rare autosomal recessive genetic 
disorder characterized by extreme sensitivity to ultraviolet (UV) rays caused by a 
deficiency in the ability to repair damage caused by sunlight (Cleaver 1968, Setlow 
et al. 1969). Individuals with XP exhibit skin malignancies and cancer at a young 
age. Further support for the critical role of DNA repair in preventing cancer in 
humans came from the discovery of other DNA repair mechanisms, summarized in 
this chapter (Figure 18.1). The mechanism through which DNA is repaired depends 
on the type and extent of the DNA damage. In mammalian cells, there are six 
major DNA repair pathways with unique—but sometimes overlapping—functions, 
to mend the damage caused by exogenous DNA-damaging agents (including che-
motherapy and radiotherapy) and damage caused by normal endogenous cellular 
processes (Kelley and Fishel 2008).
18.1.1  direct reversaL (dr)
In humans, there is only one type of DNA damage that can be repaired by direct 
chemical reversal. This mechanism can only repair one type of lesion and does not 
involve breakage of the phosphodiester backbone; thus, not requiring a template 
for the repair. The DR pathway removes alkyl groups (CH3-) at the O6 position of 
guanine by direct transfer to O6-methylguanine-DNA methyltransferase (MGMT) 
(Tano et al. 1990, Natarajan et al. 1992). MGMT transfers the methyl group to a 
cysteine residue in the protein. In this process, each MGMT molecule can only be 
used once. Impairment of the DR pathway would allow the O6-methylguanine to pair 
with thymine instead of cytosine, leading to G to A mutations (Kaina et al. 2007). 
When MGMT is unsuccessful in removing O6-methylguanine during DR, the mis-
match repair (MMR) pathway can recognize and fix the resulting O6-methylguanine 
mispairs (Luo et al. 2010). Interestingly, glioma patients with MGMT gene inacti-
vation, which would render the tumors incapable of repairing O6-methylguanine, 
have better survival rates than patients with active MGMT following treatment with 
alkylating agents such as carmustine and temozolomide (Esteller et al. 2000, Hegi et 
al. 2005). As one would predict, lack of MMR has also been shown to render tumors 
resistant to alkylating agents, even in the absence of MGMT (Liu, Markowitz, and 
Gerson 1996).
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18.1.2  Base eXcisioN repair (Ber)
BER is one of three excision repair pathways that happen to repair single stranded 
DNA damage. BER removes small, non-bulky lesions (do not distort the DNA helix) 
produced by alkylation, oxidation or deamination of bases. In this DNA repair 
mechanism, a DNA glycosylase-type enzyme removes a single damaged DNA base, 
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FIGURE 18.1 DNA repair pathways in humans. DNA repair pathways and their corre-
sponding type of DNA damage and sources of endogenous and exogenous agents are sum-
marized in this figure.
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forming an apurinic/apyrimidinic site (AP site). Additional steps including DNA 
backbone incision, gap filling, and ligation then repair the resulting AP site. Thus, 
a characteristic of BER is the diversity of the DNA glycosylases, which recognize 
specific substrates. Either the short-patch (single nucleotide replacement) or long-
patch (two to eight nucleotides are synthesized) BER pathway can process the result-
ing single-strand break that results after cleavage by AP endonucleases. Short-patch 
BER repairs most AP sites, while oxidized and reduced AP sites are preferentially 
repaired through the long-patch pathway. BER is important to removing damaged 
bases that could lead to mutations by base mispairing or lead to breaks in DNA dur-
ing replication.
In human cancer, C to T transition mutations at CpG dinucleotide sites are the 
most common kind of genetic alteration. In part, these mutations arise from the 
spontaneous deamination of methylated cytosines (5-methylcytosine) (Pfeifer 2006). 
Methyl-CpG binding domain protein 4 (MBD4) and thymine DNA glycosylase 
(TDG) are two BER glycosylases responsible for binding and removing mismatched 
thymine from DNA (Hendrich et al. 1999, Yoon et al. 2003). Mutations in MBD4, 
but not TDG, have been observed with cancers with genomic instability (Bader et 
al. 1999).
Another BER enzyme which, when mutated, may be involved in carcinogenesis is 
OGG1 (Chevillard et al. 1998, Shinmura and Yokota 2001). OGG1 is the glycosylase 
responsible for the excision of 8-oxoguanine, a mutagenic base byproduct that occurs 
as a result of exposure to reactive oxygen (Arai et al. 1997). Unrepaired 8-oxoguanines 
lead to G to T or G to C transversions.
18.1.3  NucLeotide eXcisioN repair (Ner)
NER is another excision repair pathway involved in the repair of single stranded 
DNA damage. In NER, large adduct and bulky DNA lesions that cause a significant 
distortion of the DNA double helix are excised within a string of nucleotides and 
replaced with DNA as directed by the undamaged template strands. Thus, NER is 
the DNA repair mechanism used only when one of the two DNA strands is dis-
turbed. This type of damage usually occurs as a result of cross-linking agents (e.g. 
UV radiation) and base-damaging carcinogens (Luo et al. 2010).
NER is a multi-step repair process that involves more than 30 proteins, listed 
in Table 18.1. There are two NER sub-pathways: global genomic repair (GGR) and 
transcription coupled repair (TCR). GGR acts throughout the genome, regard-
less of whether the specific sequence is the transcribed or non-transcribed strand 
of a gene (Sugasawa et al. 2001, Riedl, Hanaoka, and Egly 2003). As the name 
indicates, the TCR repair machinery removes lesions only from the transcribed 
strand of active genes, removing distorting lesions that block transcriptional 
elongation by RNA polymerases (Fousteri and Mullenders 2008, Hanawalt and 
Spivak 2008). The protein complexes that recognize the DNA damage site and 
initiates DNA repair determine the NER sub-pathway selection (Luo et al. 2010). 
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TABLE 18.1
NER Associated Genes
Human Gene Protein Subpathway Function in NER
CCNH Cyclin H Both CDK Activator Kinase (CAK) subunit
CDK7 Cyclin Dependent 
Kinase (CDK)7
Both CAK subunit
CETN2 Centrin-2 GGR Damage recognition; forms complex with 
XPC
DDB1 DDB1 GGR Damage recognition; forms complex with 
DDB2
DDB2 DDB2 GGR Damage recognition; recruits XPC
ERCC1 ERCC1 Both Involved in incision on 3’ side of damage; 
forms complex with XPF
ERCC2 XPD Both ATPase and helicase activity; transcription 
factor II H (TFIIH) subunit
ERCC3 XPB Both ATPase and helicase activity; transcription 
factor II H (TFIIH) subunit
ERCC4 XPF Both Involved in incision on 3’ side of damage; 
structure specific endonuclease
ERCC5 XPG Both Involved in incision on 5’ side of damage; 
stabilizes TFIIH; structure specific 
endonuclease
ERCC6 CSB TCR Transcription elongation factor; involved in 
transcription coupling and chromatin 
remodeling
ERCC8 CSA TCR Ubiquitin ligase complex; interacts with CSB 
and p44 of TFIIH
LIG1 DNA Ligase I Both Final ligation
MNAT1 MNAT1 Both Stabilizes CAK complex
MMS19 MMS19 Both Interacts with XPD and XPB subunits of 
TFIIH helicases
RAD23A RAD23A GGR Damage recognition; forms complex with 
XPC
RAD23B RAD23B GGR Damage recognition, forms complex with 
XPC
RPA1 RPA1 Both Subunit of RFA complex
RPA2 RPA2 Both Subunit of RFA complex
TFIIH Transcription 
factor II H
Both Involved in incision, forms complex around 
lesion
XAB2 XAB2 TCR Damage recognition; interacts with XPA, 
CSA, and CSB
XPA XPA Both Damage recognition
XPC XPC GGR Damage recognition
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The xeroderma pigmentosum group C protein, encoded by the XPC gene is a sub-
unit of these damage recognition complexes and is essential for GGR (Friedberg 
2001, Riedl, Hanaoka, and Egly 2003). For the TCR pathway, recognition of the 
DNA damage-blocked RNA polymerase by transcription-repair coupling factors 
is important. After damage recognition, both NER subclasses have the same or 
similar subsequent steps involved in nucleotide excision and gap filling by DNA 
polymerases.
18.1.4  mismatch repair (mmr)
The last excision repair pathway involved in the repair of single stranded DNA dam-
age is MMR. During DNA replication mistakes can occur that escape the proofread-
ing activity of DNA polymerase as it copies the two strands. The MMR pathway is 
responsible for recognizing and repairing single-base insertions, deletions, and mis-
matches that arise during normal DNA replication process (Luo et al. 2010, Fleck 
and Nielsen 2004). These errors that escape the proofreading activity of DNA poly-
merases happen with a frequency of about 1 in 109–1010 base pairs per cell division 
(Iyer et al. 2006). Furthermore, exposure to exogenous agents or endogenous reactive 
species may cause base modifications that lead to nucleotide mispairing (Li 2008). 
Loss of MMR affects genome stability (including microsatellite instability), which 
causes cancer predisposition (Jiricny 2006). In this pathway, PMS2, MLH1, LSH6, 
and MSH2 are proteins that recruit EXO1 to excise the segment of mutant DNA 
strand. Then DNA polymerases replace the missing section of the strand with a new 
section and the damage is repaired. The vast majority of hereditary non-polyposis 
colorectal cancers (HNPCC) are attributed to mutations in the MSH2 and MLH1 
genes (Bronner et al. 1994).
18.1.5  homoLogous recomBiNatioN (hr)
HR is one of two mechanisms through which DNA double-strand breaks can be 
repaired. DNA damage that has not been repaired before replication can cause 
DNA polymerase blockage, resulting in DNA double-strand breaks. HR is the 
repair pathway used to fix double-strand breaks detected during the S/G2 phases 
of the cell cycle, when a homologous template via the sister chromatid is avail-
able. Since HR requires a long homologous sequence to guide the repair, it is 
highly accurate in its repair (Fleck and Nielsen 2004). The DNA checkpoint 
responses are responsible for the regulation of double-strand break ends process-
ing, which will determine which DNA double-strand break repair mechanism 
will perform the repair. This is a crucial stage in the recombination process 
(Lazzaro et al. 2009).
Two of the most studied genes and proteins that are involved in this repair path-
way are BRCA1 and BRCA2. These tumor suppressor proteins form a complex along 
with RAD51 to repair DNA double-strand breaks (Duncan, Reeves, and Cooke 
1998, Yoshida and Miki 2004). Cells missing BRCA1 and BRCA2 have a decreased 
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rate of HR. Mutations in the BRCA1 and BRCA2 genes have been associated with 
considerably increased risk for breast and ovarian cancer (Miki et al. 1994, Wooster 
et al. 1994).
18.1.6  NoN-homoLogous eNd joiNiNg (Nhej)
NHEJ is the other pathway that repairs double-strand breaks in DNA. Unlike HR, 
NHEJ has the potential to relegate any type of DNA ends, without the need for a 
homologous template. Since NHEJ does not require an identical copy of DNA as 
a template, it is not restricted to a certain phase of the cell cycle, and it is prone to 
imprecise repair leading to loss or addition of bases in the ligation process (Fleck 
and Nielsen 2004). Inactivation of CDK1 increases NHEJ events in the G2 phase of 
the cell cycle (Lazzaro et al. 2009). DNA strands that are not repaired completely by 
NHEJ are subject to repair by HR (Essers et al. 2000).
The initial step in NHEJ is the recognition and binding of the Ku heterodimer at 
the DNA double-strand break (Mari et al. 2006). The Ku heterodimer is composed 
of Ku70 and Ku80, encoded by the XRCC6 and XRCC5 genes, respectively. Once the 
Ku heterodimer is bound the DNA double-strand break ends, it serves as a scaffold 
to recruit the other NHEJ factors to the damage site. No spontaneous Ku mutations 
have been found in humans, suggesting that both Ku70 and Ku80 are likely required 
for viability.
18.2  EPIGENETICS IN CANCER
It was long thought that tumorigenesis was mostly driven by genetic mutations and 
genomic instability. With the advent of whole-genome sequencing, cancers with a low 
rate of mutations have been identified and epigenetics has gained an ever-increasing 
role in the process of tumor progression (Zhang et al. 2012, Feinberg, Koldobskiy, 
and Gondor 2016). Epigenetics is defined as the inheritable changes in gene expres-
sion with no alterations in DNA sequences. During the past few years several studies 
showed the connection between disruptions of the epigenome, defined as the com-
bination of changes in gene expression, and tumor progression. In the eukaryotic 
nucleus, DNA is compacted into a chromatin structure with the nucleosome as the 
basic unit, in which 147 bases of DNA surround each histone octamer. The histone 
octamer includes two elements of the core histone (H3, H4, H2A, and H2B) (Luger 
et al. 1997). Unlike the other histones H1, the “linker “histone, is not a component 
of the nucleosome. It interacts at the DNA entrance and exit site of the nucleosome 
and the linker DNA that connects adjacent nucleosome. There are three main epi-
genetic modifications that regulate chromatin structure and gene expression: DNA 
methylation, histone covalent modification and microRNAs (miRNAs) (Figure 18.2). 
All together, they constitute the “epigenetic code,” that is capable of modulating the 
expression of the different cell types. Disruption of epigenetic processes can lead 
to altered gene function and malignant cellular transformation (Sharma, Kelly, and 
Jones 2010).
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18.2.1  dNa methyLatioN
DNA methylation is a covalent modification of DNA that has been described in 
bacteria, plants, and mammals. It can occur following DNA replication, in order 
to re-establish the preexisting DNA methylation pattern or de novo, and in both 
situations acts to repress gene transcription (Chen et al. 2014). In eukaryotic cells, 
the 5’ methyl group is added to the cytosine base, and this modification is most 
frequently found in the context of CpG dinucleotides. S-adenosyl-methionine is the 
methyl donor in a reaction catalyzed by the DNA methyltransferase (DNMT) family, 
including DNMT1, DNMT3A and DNMT3B. DNMT1 is responsible for the meth-
ylation of hemi-methylated DNA and thus DNA methylation maintenance, whereas 
DNMT3A and DNMT3B are involved in de novo DNA methylation, but they can 
also participate in methylation maintenance (Castillo-Aguilera et al. 2017). It can be 
speculated that DNA methylation is capable of preventing gene transcription either 
by blocking the combination of a transcription factor and its binding sites, or through 
the recruitment of methylated binding domain proteins that mediate inhibition of 
gene expression.
In some areas of the genome, CpG sites are concentrated in short CpG-rich DNA 
fragments or DNA fragments in the long repeat so-called ‘CpG islands’. CpG island-
containing gene promoters are usually un-methylated in normal cells to maintain 
euchromatic structure, which is the transcriptional active conformation allowing 
gene expression (Chen et al. 2014).
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FIGURE 18.2 Euchromatin and heterochromatin landscape. Schematic representation of 
the nucleosome octamers. Condensed chromatin is not accessible to transcription factors 
(repressed chromatin, left). Epigenetics modifiers can render chromatin accessible to tran-
scription factors and RNA polymerase II (active chromatin, right).
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18.2.2  histoNe modificatioNs
The histone octamer, the basic element of the nucleosome core particle, con-
sists of two copies of each core histone proteins (H2A, H2B, H3, and H4). The 
N-terminals of histones protrude out of the nucleosome core, and amino acids 
of N-terminals easily undergo a series of covalent modifications, such as meth-
ylation, acetylation, phosphorylation, ubiquitination and sumoylation (Figure 
18.3) (Tessarz and Kouzarides 2014, Cheung, Allis, and Sassone-Corsi 2000). 
These post-translational modifications can regulate important processes such as 
gene transcription, X-chromosome inactivation, mitosis, heterochromatin forma-
tion, DNA repair, and replication (Kouzarides 2007). Regarding gene transcrip-
tion, histone H3 lysine 9 acetylation (H3K9ac), H3 serine 10 phosphorylation 
(H3S10ph), and H3 lysine 4 tri-methylation (H3K4me3) are reported to be associ-
ated with transcriptional activation. Conversely, H3K27me3 and hypoacetylation 
of H3 and H4 are correlated with transcriptional repression. Importantly, a large 
body of evidence supports a scenario in which combinatorial modifications corre-
spond to specific functional chromatin states. Individual post-translational modi-
fications can favor or inhibit consequent modifications on nearby residues of the 
same tail (Fischle, Wang, and Allis 2003, Latham and Dent 2007). For example 
phosphorylation of Ser-10 on H3, is a positive signal for subsequent acetylation 
at K14 on the same tail (Lo et al. 2000, Cheung, Allis, and Sassone-Corsi 2000) 
whereas histone deacetylation and methylation of H3-K9 lysine represses tran-
scription (Fuks 2005).
18.2.3  microrNas
miRNA encode small noncoding RNA molecules (19–25 nucleotides in length) that 
are complementary to the 3’ untranslated regions of target mRNAs. This results in 
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79          36                             27            23              18 17      14               9                  4     2
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FIGURE 18.3 Predominant post-translational modifications of histones H3 and H4. Partial 
view of histones H3 and H4 N-terminal tail with the main post-translational modifications 
known to lead gene transcriptional activation or repression. The corresponding residue num-
ber is shown under each modified amino acid. Marked in green are the amino acids and 
post-translational modifications that lead to transcriptional activation. In red are the amino 
acid residues and post-translational modifications that lead to transcriptional repression. 
In purple is the amino acid that can be modified to both active and repressive transcription. 
Me = methyl group, P = phosphate group, Ac = acetyl group.
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gene silencing through translational repression or target mRNA degradation (Bartel 
2009). Studies on miRNAs have demonstrated how they regulate gene expression 
also at transcriptional level, and not only at post-transcriptional level as described 
above. Promoter-associated RNA (paRNA) can also regulate transcription of genes 
by targeting the promoter (Costa 2010). PaRNA can also modify the recruitment of 
the epigenetic machinery to enhance or silencing transcription of mRNA (Yan and 
Ma 2012).
18.2.4  the epigeNetic cLassificatioN system for caNcer geNes
The old classification of cancer genes into dominant oncogenes (MYC, KRAS, PIK3CA, 
ABL1, BRAF) and recessive tumor suppressor genes (RB1, TP53, WT1, NF2, VHL, 
APC, CDKN2A), has been replaced by the more functional epigenetics classification 
of the cancer genes, which includes the epigenetic modifiers, the mediators and the 
modulators (Feinberg, Koldobskiy, and Gondor 2016). Epigenetic modifiers are gene 
products capable of directly modifying the epigenome through DNA methylation, 
post-translational modification of chromatin, or the alteration of the structure of the 
chromatin. The epigenetic mediators are often the targets of epigenetic modification, 
although they are rarely mutated themselves; importantly, they appear to be respon-
sible for the emergence of cancer stem cells (Feinberg, Koldobskiy, and Gondor 2016). 
Finally, the epigenetics modulators are defined as genes lying upstream of the modifi-
ers and mediators in signaling and metabolic pathways, and serving as the mechanism 
by which environmental agents, injury, inflammation, and other forms of stress push 
tissues towards a neoplastic propensity and/or increase the likelihood that cancer will 
arise when a key mutation occurs by chance.
18.2.5  epigeNetic modifier mutatioNs aNd caNcer
Epigenetic modifier mutations are a common occurrence in a wide range of cancers 
(Table 18.2). These occur in components at every level of the epigenetic machinery 
including DNA methylation and histone modification.
18.2.5.1  DNA Methylation
Hematological malignances are highly related to mutations in the DNA methylation 
machinery. These events clearly underline how epigenetics and genetics can coop-
erate in cancer initiation and progression. DNA methyltransferase3α (DNMT3A) 
mutations have been described in human acute myeloid leukemia, acute monocytic 
leukemia and T-cell lymphoma (Ley et al. 2010, Yan et al. 2011, Couronne, Bastard, 
and Bernard 2012). Moreover, DNMT3A mutations are considered a marker of poor 
prognosis both in acute myeloid leukemia and T-cell acute lymphoblastic leukemia 
(Grossmann et al. 2013, Ribeiro et al. 2012). DNMT1 mutations have been described 
in colon cancer (Kanai et al. 2003). Mutations in DNMT3B have been associated with 
a rare autosomal recessive immunoglobulin deficiency, sometimes combined with 
defective cellular immunity called immunodeficiency-centromeric instability-facial 
anomalies (ICF) syndrome (Wijmenga et al. 2000). In addition, a single nucleotide 
polymorphism (SNPs) that involves a C to T transition on the promoter of this gene 
539DNA Repair and Epigenetics in Cancer
has been associated with increased DNMT3B promoter activity and increased risk 
of lung cancer, while DNMT3B overexpression can lead to hypermethylation and 
silencing of key genes in human breast cancer cell lines (Shen et al. 2002, Roll et 
al. 2008). DNA methylation can be reversed by erasers, which are part of the epi-
genetic machinery. Among these we can find TET (Ten-eleven-translocation) and 
AID (Activation-induced cytidine deaminase) demethylases (De Carvalho et al. 
2012, Ko et al. 2010, Wu and Zhang 2010). Active DNA demethylation is currently 
TABLE 18.2
Epigenetic Modifier Mutations in Cancer
Gene Function Cancer
DNMT3A DNA methylation 
(de novo)
Acute myeloid leukemia (Ley et al. 2010); T-cell lymphoma 
(Couronne, Bastard, and Bernard 2012)
DNMT1 DNA methylation Colon cancer (Kanai et al. 2003)
DNMT3B DNA methylation 
(de novo)
Lung adenocarcinoma (Shen et al. 2002); breast cancer 
(Roll et al. 2008)
Tet2 DNA demethylation Myelodysplastic syndrome; myeloproliferative neoplasms; 
acute myeloid leukemia (Gaidzik et al. 2012)
IDH1/2 DNA demethylation Glioma (Turcan et al. 2012); acute myeloid leukemia 
(Figueroa et al. 2010)
EP300 Histone acetylation Acute myeloid leukemia (Wang, Gural et al. 2011)
HDAC1 Histone deacetylase Prostate cancer (Halkidou et al. 2004); gastric cancer (Choi 
et al. 2001)
HDAC2 Histone deacetylase Colorectal cancer (Ozdag et al. 2006)
HDAC4 Histone deacetylase Breast cancer (Sjoblom et al. 2006)
HDAC7A Histone deacetylase Colorectal tumors (Ozdag et al. 2006)
KMT2A Histone methyltransferase Acute myeloid leukemia (Thirman et al. 1993)
KMT2B Histone methyltransferase Endometrial; large intestine; lung; glioma; liver carcinoma 
(Rao and Dou 2015)
KMT2C Histone methyltransferase Endometrial; large intestine; lung; bladder carcinoma (Rao 
and Dou 2015)
KMT2D Histone methyltransferase Acute myeloid leukemia; lung large intestine carcinoma; 
bladder carcinoma (Rao and Dou 2015)
EZH2 Histone methyltransferase Non-Hodgkin lymphoma; solid tumors; T-cell leukemia 
(Feinberg, Koldobskiy, and Gondor 2016)
NSD1 Histone methyltransferase Acute myeloid leukemia (Varier and Timmers 2011)
SMYD3 Histone methyltransferase Colon; breast; hepatocellular carcinoma (Varier and 
Timmers 2011)
G9A Histone methyltransferase Hepatocellular carcinoma (Varier and Timmers 2011)
PRMT1 Arginine methyltransfrase Breast cancer (Gao et al. 2016)
PRMT5 Arginine methyltransfrase Hematologic and solid tumors (Tarighat et al. 2016)
LSD1 Histone demethylase Bladder; colorectal cancer (Rotili and Mai 2011)
KDM6A Histone demethylase Myeloma; renal cell carcinoma (Rotili and Mai 2011)
BRCA1 Ubiquitin ligase Breast; ovarian cancer (Zhu et al. 2011)
USP22 Ubiquitin hydrolase Breast cancer (Zhang et al. 2011)
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thought of as being a stepwise process. First 5-methylcytosine (5mC) is converted 
into 5- hydroxymethylcytosine (5hmC) by the TET family of enzymes. Subsequently 
5hmC can be deaminated by the AID/APOBEC family members to form 5-hydroxy-
methyluracil (5hmU). The DNA excision repair system can finally replace the cytosine 
without the methyl group (Bhutani, Burns, and Blau 2011). Three TET family mem-
bers (TET1, TET2, and TET3) have been reported so far and each protein seems to 
have a distinct function in different cellular contexts (Cimmino et al. 2011). Mutations 
in TET2 including frame shift, nonsense and missense mutations, have been found 
in various myeloid neoplasms and gliomas (Gaidzik et al. 2012). Cytosolic isoci-
trate dehydrogenase 1/2 (IDH) mutants display global DNA hypermethylation along 
with the accumulation of 2-hydroxyglutarate, and they are also capable of impair-
ing TET2 function. IDH1/2 mutations were mutually exclusive with mutations in the 
α-ketoglutarate-dependent enzyme TET2, while TET2 loss-of function mutations (a 
type of mutation in which the altered gene product lacks the molecular function of the 
wild-type gene mutations) are associated with similar epigenetic defects as IDH1/2 
mutants (Figueroa et al. 2010). IDH1/2 mutations are described in different kind of gli-
omas and leukemias (Turcan et al. 2012). These mutants show impaired hematopoietic 
differentiation (Figueroa et al. 2010), and impaired cell differentiation (Lu et al. 2012).
18.2.5.2  Histone Acetylation and Deacetylation
The acetylation of lysine on histone is generally associated with active gene tran-
scription. Acetyltransferase (HATs) can be grouped into three main categories 
according to their sequence similarity: Gcn5-related–N-acetyltransferase (GNAT), 
MYST (acronym for the founding members MOZ, Ybf2, Sas2, TIP60), and orphan 
(p300/CBP and nuclear receptors) (Yang 2004). Several mutations such as amplifica-
tions, point mutations or translocations of HATs have been described. Several publi-
cations connected acetyltransferase mutation to different types of cancer. Mutations, 
translocations or deletions of these genes are observed in colon, uterine, lung tumors, 
and leukemia (Esteller 2007). HATs can also modulate the activity of fusion pro-
teins. It has been previously described how AML1-ETO, the most frequent fusion 
protein in acute myeloid leukemia needs p300-mediated site-specific acetylation to 
drive leukemogenesis (Wang, Gural, et al. 2011).
Histone deacetylases (HDAC) are erasers that can remove acetyl. There are five 
classes of histone deacetylases:
-class I: HDAC1, HDAC2, HDAC3, and HDAC8
-class IIa: HDAC4, HDAC5, HDAC7, HDAC9
-class IIb: HDAC6 and HDAC10
-class III: Sirtuins (SIRT1-7)
-class IV: HDAC11
Somatic changes in HDAC genes are implicated in cancer progression. HDAC1, 
HDAC5 and SIRT1 are downregulated in some renal, bladder, and colorectal 
tumors (Ozdag et al. 2006). HDAC1 is overexpressed in prostate and gastric cancer 
(Halkidou et al. 2004, Choi et al. 2001). HDAC2 mutations correlate with colorectal 
cancer (Ozdag et al. 2006), gastric (Ropero et al. 2006), and endometrial primary 
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tumors (Ropero et al. 2006). The loss of HDAC2 protein expression renders those 
cells more resistant to the usual anti-proliferative and pro-apoptotic effect of his-
tone deacetylase inhibitors. HDAC4 mutations have been identified in breast cancer 
(Sjoblom et al. 2006). HDAC5 is overexpressed in some colorectal tumors (Ozdag 
et al. 2006). And, higher expression of HDAC7A was observed in most colorectal 
tumors (Ozdag et al. 2006). Understanding the role of epigenetics modifiers in can-
cer can open new avenues for medical treatment through the identification of new 
drugs that specifically target these factors.
18.2.5.3  Histone Methylation
Methylation of arginine and lysine residues on histone protein tails can regulate 
chromatin structure and gene expression. One well-known example for alterations 
in histone methylation is mixed lineage leukemia (MLL). MLL1 (also known as 
KMT2A) is the human homolog of the trithorax (trx) in Drosophila. The trithorax 
group of proteins typically function in large complexes formed with other proteins 
and are most commonly associated with gene activation. MLL regulates H3K4me3, 
an active mark for transcription. Translocations of MLL1 with multiple different 
partners can originate fusion proteins that have abnormal patterns of H3K4me3 
and/or abnormal patterns of histone modifier recruitment resulting in tumorigen-
esis. Rearrangement of the MLL1 gene has been described in acute lymphoblastic 
and acute myeloid leukemia (Thirman et al. 1993). Mutations in MLL1 have also 
been described in a large spectrum of solid tumors (colon, lung, bladder, endome-
trial, and breast cancers) (Rao and Dou 2015). Mutations in the coding region of 
MLL2 (also known as KMT2B), another member of the MLL family of methylases, 
occur in endometrial, large intestine, lung, glioma, and liver carcinomas (Rao and 
Dou 2015). To date, hundreds of MLL3 (known as KMT2C) and MLL4 (known as 
KMT2D) mutations have been identified, making them among the most frequently 
mutated genes in human cancer. MLL3 mutations are prevalent in lung, large intes-
tine, breast, endometrial, and bladder carcinomas. All these together account for 
60% of the total KMT2C mutations identified (Rao and Dou 2015). Nonsense, mis-
sense and frameshift mutation of MLL4 (known as KMT2D) have been related to 
acute myeloid leukemia, lung, large intestine, endometrial carcinomas, and medul-
loblastoma (Rao and Dou 2015). EZH2 (enhancer of zeste homologue 2) is a mem-
ber the Polycomb repressive complex 2 (PRC2). EZH2 regulates H3K27me3 and 
there are two different classes of mutations that affect its function. Gain-of-function 
hotspot mutations (a type of mutation in which the altered gene product possesses a 
new molecular function or a new pattern of gene expression) and amplification have 
been reported in non-Hodgkin lymphomas and solid tumors. These events suggest 
how these tumors require an increased level of H3K27 tri-methylation (Feinberg, 
Koldobskiy, and Gondor 2016). On the contrary, loss-of-function mutations (a type 
of mutation in which the altered gene product lacks the molecular function of the 
wild-type gene) of EZH2 have been described in myeloid malignancies, head and 
neck squamous carcinomas, and T-cell leukemia (Feinberg, Koldobskiy, and Gondor 
2016). Other lysine histone methyl-transferases (HMTs) are aberrantly expressed in 
several cancers. NSD1 (Nuclear Receptor Binding SET Domain Protein 1) methyl-
ates Lys-36 of histone H3 and Lys-20 of histone H4 (in vitro). This transcriptional 
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intermediary factor is capable of both negatively or positively influencing transcrip-
tion, depending on the cellular context. NSD1 translocations have been described in 
acute myeloid  leukemia (Varier and Timmers 2011). SMYD3 (SET and MYND 
Domain Containing 3)  specifically methylates Lys-4 of histone H3, inducing di- 
and tri-methylation, but not mono-methylation. It also methylates Lys-5 of histone 
H4. SMYD3 overexpression has been described in colon, breast, and hepatocellu-
lar carcinoma (Varier and Timmers 2011). G9a regulates mono- and di-methylation 
of Lys-9 of histone H3 (H3K9me1 and H3K9me2, respectively) in euchromatin. 
H3K9me represents a specific tag for epigenetic transcriptional repression. G9a 
overexpression has been detected in hepatocellular carcinoma (Varier and Timmers 
2011). Evidence for the role of arginine HMTs in tumorigenesis has not been as well 
established as that of lysine HMTs. PRMT1 (Protein Arginine Methyltransferase 1) 
constitutes the main enzyme that mediates mono-methylation and asymmetric di-
methylation of histone H4 Arg-3 (H4R3me1 and H4R3me2a, respectively), a spe-
cific tag for epigenetic transcriptional activation. Upregulation of PRMT1 expression 
has been described in breast cancer (Gao et al. 2016). PRMT5 (Protein Arginine 
Methyltransferase 5) mediates the formation of omega-N mono-methyl-arginine 
(MMA) and symmetrical di-methylarginine (sDMA). Overexpression of PRMT5 
has been reported in hematologic and solid malignancies (mantle cell lymphoma, 
lung and bladder cancer, gastric cancer, germ cell tumors) (Tarighat et al. 2016).
Histone demethylases (KDMs) are erasers responsible for removing histone meth-
ylation. Aberrant expression of LSD1 (Lysine-specific histone demethylase 1), that 
demethylates both Lys-4 (H3K4me) and Lys-9 (H3K9me) of histone H3, has been 
shown in many types of cancers (bladder, small cell lung, and colorectal cancer) 
(Rotili and Mai 2011). Downregulation or inactivation of KDM6A/UTX (lysine-
specific demethylase 6A), specific for demethylation of H3K27me3/me2, have been 
reported in various type of cancers such multiple myeloma, esophageal squamous 
cell carcinomas, and renal cell carcinomas (Rotili and Mai 2011). Another large 
class of histone demethylases is composed of the Jumonji family of Lysine demeth-
ylases. These enzymes can demethylate all three lysine methylation states (tri-, di-, 
and mono-methylation) at H3K4, H3K9, H3K27, and H3K36, as well as H1K26. 
Six different subfamilies (JMJD1s, JMJD2s, JARID1s, UTX/Y-JMJD3, PHFs, and 
FBXLs) of JmjC histone demethylases have been identified, which have different 
histone sequence and methylation state selectivity. Misregulation of JmjC KDMs 
has significantly been implicated in cancer initiation and progression (Rotili and 
Mai 2011).
18.2.5.4  Histone Ubiquitination
Histone H2A was the first protein identified to be modified by ubiquitination 
(Goldknopf et al. 1975). H2A and H2B are two of the most abundant ubiquitinated 
proteins present in the nucleus (5–15% for H2A and 1–2% for H2B) (Goldknopf et 
al. 1975, West and Bonner 1980, Robzyk, Recht, and Osley 2000). The most fre-
quent forms of histone ubiquitination are mono-ubiquitination of H2A (H2Aub) and 
H2B (H2Bub). The residues that are normally mono-ubiquitinated are: Lys-119 for 
H2A, and Lys-123 in yeast, or Lys-120 in vertebrate for H2B (Goldknopf et al. 1975, 
West and Bonner 1980). It has been reported that H3 and H4 and linker histone H1 
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could be ubiquitinated, but the biological function still has to be elucidated (Pham 
and Sauer 2000, Jason et al. 2002, Wang et al. 2006). The modifier enzymes respon-
sible for ubiquitination are called histone ubiquitin ligases. The first to be identified 
was RING1B (E3 ubiquitin ligase), and it is responsible for Lys-119 H2A mono- 
ubiquitination. It belongs to the Polycomb group proteins so it is related with gene 
silencing, while on the contrary H2B ubiquitination has been related with gene tran-
scription activation (Cao and Yan 2012). Different studies underline how histone ubiq-
uitination and other histone modifications are interconnected. It has been described 
in literature how histone H2B mono-ubiquitination is required for subsequent H3K4 
methylation and H3K79 methylation, all markers of active gene transcription (Dover 
et al. 2002, Sun and Allis 2002, Lee, Shukla et al. 2007). BRCA1, a known tumor 
suppressor gene, contains in its RING finger an E3 ubiquitin ligase and it can catalyze 
H2A mono-ubiquitination in vivo (Zhu et al. 2011). Inactivation of BRCA1 causes the 
development of breast and ovarian cancer. RNF20, the major H2B specific E3 ubiqui-
tin ligase in mammals, is considered a putative tumor suppressor gene since its deple-
tion can increase the expression of c-myc and c-FOS, two proto-oncogenes (Shema 
et al. 2008). Histone ubiquitination can be reversed by ubiquitin hydrolase. USP22 
can remove ubiquitin from monoubiquitinated H2A and H2B (Zhang, Varthi et al. 
2008, Zhao et al. 2008). Elevated expression of USP22 is related with poor prognosis 
in patients with breast cancer (Zhang et al. 2011). All of this evidence underlines the 
important role played by histone ligase/hydrolase for normal cell function and makes 
these enzymes “drug-able” targets for future cancer therapies.
The expression patterns of histone modifiers in human cancer suggest these 
genes are important in neoplastic transformation and have characteristic patterns 
of expression depending on tissue of origin, with implications for potential clinical 
application.
18.2.6  epigeNetic readers
Readers typically provide an accessible surface (such as a cavity or surface groove) to 
accommodate a modified histone residue, and determine the modification (acetyla-
tion vs. methylation) or state specificity (such as mono- vs. tri-methylation of lysine) 
(Yun et al. 2011). The SRA (Set and Ring Associated) domain of Uhrf1 behaves likes 
a “hand” with two fingers, capable of flipping out the methylated cytosine with sub-
sequent recruitment of DNMT1 (DNA methyltransferase 1) to methylate the cyto-
sine of the newly synthetized DNA strand. Uhrf1 TTD (Tandem Tudor Domain) and 
PHD (Plant Homo Domain) are instead capable of recruiting respectively the histone 
methyltransferases Suv39H1 or G9a. Uhrf1 overexpression has been reported to be 
upregulated in various types of cancers, including breast, lung, pancreatic, astro-
cytomas, cervical, bladder cancer, retinoblastoma, and leukemia (Kofunato et al. 
2012, Benavente et al. 2014, Alhosin et al. 2016). Hells (helicase, lymphoid specific, 
also known as lymphoid-specific helicase) is a putative chromatin remodeler belong-
ing to the SWI/SNF subfamily that plays a central role at repetitive pericentromeric 
heterochromatin. Hells can remodel chromatin in order to render it accessible to 
DNA methyltransferase enzymes Dnmt3a or Dnmt3b, but not Dnmt1, and therefore 
supports de novo DNA methylation and stable gene silencing. Hells upregulation 
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has been described in human retinoblastoma and human prostate cancer (Benavente 
et al. 2014, von Eyss et al. 2012). BRD4 is a member of the bromodomain proteins 
of epigenetics readers. A bromodomain is an approximately 110 amino acid protein 
domain that recognizes acetylated lysine residues, such as those on the N-terminal 
tails of histones. The fusion of BRD4 with nuclear protein in testis (NUT) results in 
the development of NUT midline carcinoma (French et al. 2001). Downregulation of 
BRD7 is observed in hepatocellular carcinoma, and lower level of BRD7 expression 
is also used as an indicator of poor prognosis in patients with osteosarcoma (Chen 
et al. 2016). BRD8 somatic mutations have been reported in whole genome sequenc-
ing of human hepatocarcinoma (Fujimoto et al. 2012, Fujisawa and Filippakopoulos 
2017). Selective inhibition of these epigenetic readers may be a novel tool for cancer 
treatment.
18.2.7  epigeNetic mediators aNd caNcer
Epigenetics mediators are normally regulated in cancer by epigenetics modulators 
in order to increase pluripotency or survival. These genes are capable of counteract-
ing proper maturation programs when ectopically expressed or overactive, and in 
order to do that, the mediators are capable of influencing the epigenetic states that 
define differentiated cell types. Large blocks of repressive H3K9me2 and H3K9me3 
modifications along with DNA methylation coordinate the cell-type-specific repres-
sion of developmentally regulated genes. These areas are called large organized 
chromatin K9 modifications (LOCKs) and are largely absent from embryonic stem 
cells and cancer cell lines (Wen et al. 2009). Well-known pluripotency factors such 
as NANOG or OCT4 (also known as POU5F1) and some WNT signaling members 
belong to this category (Feinberg, Koldobskiy, and Gondor 2016). NANOG is a tran-
scription factor required for maintaining the pluripotency of embryonic stem cells 
and is not expressed in most normal adult tissues. However, several studies described 
NANOG overexpression on several tumors, including breast cancer. NANOG is not 
capable of inducing the mammary tumor alone, but when co-expressed with Wnt-1, 
promotes cell migration and invasion (Lu et al. 2014). OCT4 is another factor that 
plays a pivotal role as key regulator in pluripotency. It is believed that OCT4 main-
tains the pluripotency of spermatogonial (the earliest stage in the spermatocitic 
ontogeny) stem cells and keeps them in an undifferentiated, self-renewing state. Its 
aberrant expression may contribute to the neoplastic process in cancer cells (Gidekel 
et al. 2003). Moreover, the sex-determining Y-box (SOX2) gene, another important 
pluripotency factor, is amplified in small-cell lung cancer and squamous cell car-
cinomas of the lung and esophagus (Rudin et al. 2012, Bass et al. 2009). SOX2 is 
highly expressed in nasopharyngeal carcinoma, and lung adenocarcinoma (Luo et 
al. 2013, Chiou et al. 2010). NANOG and OCT4 overexpression are associated with 
increased metastatic potential in breast cancer and lung adenocarcinoma (Lu et al. 
2014, Wang et al. 2014, Chiou et al. 2010). In conclusion OCT4, NANOG, and SOX2 
altered expression is capable of preventing proper maturation of the stem cells, and 
contributing to the development of different tumors. Finally, these genes could be 
potential markers of prognosis and a novel target of therapy for these tumors.
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18.2.8  epigeNetic moduLators aNd caNcer
Epigenetic modulators are factors capable of influencing the activity of the epigenetics 
modifiers causing the destabilization of differentiation-specific epigenetic states. An 
example of epigenetic modulators is oncogenic RAS signaling. All RAS protein family 
members belong to a class of protein called small GTPase and are involved in transmit-
ting signals within cells (cellular signal transduction). KRAS transformation, a mem-
ber of the RAS genes, can drive the downregulation of TET enzymes (histone lysine 
demethylases described above) and this event increases DNA methylation, that facili-
tates the silencing of tumor suppressor genes (Wu and Brenner 2014). Moreover, about 
70% of colorectal cancers with a KRAS mutation show chemical marks that “switch 
off” the expression of genes, known to suppress the growth of tumors. In actively 
growing human diploid fibroblasts, the INK4A-ARF locus is silenced by histone H3 
lysine 27 tri-methylation (H3K27me3) directed by Polycomb group proteins. When 
such cells are exposed to cellular stress, such as oncogenic signals, the H3K27me3 
mark on the locus is decreased, resulting in expression of INK4A-ARF tumor suppres-
sor genes. KRAS can increase the level of the ZNF304 transcription factor that binds 
to the repressor complex made by KAP1-SETDB1-DNMT1. This event causes the lack 
of activation of the INK4A-ARF locus (Serra et al. 2014). Another example is STAT3 
(Signal transducer and activator of transcription 3) gene. This gene is an important 
regulator of NANOG, OCT4, and SOX2 expression (all epigenetic mediators described 
above) (Do et al. 2013). STAT3 is also capable of promoting the acquisition of stem cell 
features in pancreatic cancer (Tyagi et al. 2016), so it can be speculated that external 
signals may lead to the activation of the epigenetic mediators through STAT3 activa-
tion. Moreover STAT3 is capable of interacting with epigenetic modifiers such as p300 
histone acetyltransferase (HAT), or DNMT1 influencing gene expression and cell-type 
specific transcription (Hutchins, Diez, and Miranda-Saavedra 2013).
TP53, a tumor suppressor gene, is also capable of acting as an epigenetic modula-
tor. TP53 gain of function mutations can induce the expression of MLL1 and MLL2 
(mixed-lineage leukemia) genes, and this results in genome-wide increase in H3K4 tri-
methylation and gene transcription activation (Zhu et al. 2015). Moreover, mutated p53 
can help in maintaining an open chromatin conformation at the VEGFR2 promoter 
through the recruitment of the SWI/SNF complex (Pfister et al. 2015). Bi-allelic 
inactivation of RB1 (retinoblastoma 1) gene, another important tumor suppressor, 
drives the development of human retinoblastoma, a pediatric tumor of the retina. 
Whole-genome sequencing of human retinoblastomas identified no genetic lesions 
in known tumor suppressor genes or oncogenes, other than RB1. Furthermore, the 
epigenetic profile showed profound changes compared to that observed in normal 
retinoblasts (Zhang et al. 2012). As for epigenetic mediators, the modulators are 
important targets for the cancer predisposing environment, and their mutations can 
lead to the destabilization of the epigenome.
18.2.9  microrNa aNd caNcer
MicroRNA (miRNAs) play an important role in regulating gene expression. 
MiRNAs can be classified as oncogenic, tumor suppressor, or context dependent 
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(Kasinski and Slack 2011). For example, miR-21 and miR-155 are frequently over-
expressed in cancer, while miR-15~16 belong to the family of the onco-suppressor. 
MiR-146 instead is considered a context-dependent miRNA, because it may have 
opposing roles in tumorigenesis depending on the cellular context (Kasinski and 
Slack 2011). Interestingly it has been described in literature how miRNAs can regu-
late the expression of the epigenetic modifiers. Downregulation of miR-101 can lead 
to EZH2 (H3K27me3) overexpression in bladder and prostate cancer (Friedman et 
al. 2009, Varambally et al. 2008). Among the reported downregulated miRNAs in 
lung cancer, the miRNA miR-29 family (29a, 29b, and 29c) can target the 3’-UTRs 
of DNA methyltransferase DNMT3A and DNMT3B (de novo methyltransferases), 
two key enzymes involved in DNA methylation, that are frequently upregulated in 
lung cancer and associated with poor prognosis (Fabbri et al. 2007). In lung cancer 
miR-449 can downregulate HDAC1 expression, and this results in tumor suppres-
sion (Jeon et al. 2012, Rusek et al. 2015). Co-treatment with miR-449a and HDAC 
inhibitors had a significant growth reduction compared with HDAC inhibitor mono-
treatment. These results suggest that miR-449a/b may have a tumor suppressor func-
tion and might be a potential therapeutic candidate in patients with primary lung 
cancer. MiRNAs expression can be altered by epigenetic changes given that around 
half of the miRNA genomic sequences are associated with CpG islands (Weber et 
al. 2007). A good example is miR-127, which is embedded in a CpG island within a 
miRNA cluster. The expression of the whole cluster is downregulated or completely 
silenced in primary tumors (prostate, bladder and colon) and various cancer cell 
lines (HCT1116, HeLa and MCF7). Interestingly, miR-127 downregulation can be 
reversed using DNMT inhibitors (5-Aza-CdR) (Saito et al. 2006). MiR-9-1 and miR-
34a/b are DNA hypermethylated in breast and colon cancer respectively (Lehmann 
et al. 2007, Toyota et al. 2008). MicroRNA also play a pivotal role in the early phase 
of cancer metastasis called epithelial-to-mesenchymal transition (EMT), charac-
terized by the repression of E-cadherin. The zinc finger transcriptional repressors 
ZEB1, ZEB2, Snail1, and Twist1 are involved in E-cadherin regulation; and thus, 
EMT. The miR-200 family can inhibit ZEB in several cancer types such as breast, 
bladder, and ovarian cancers (Bendoraite et al. 2010, Gregory et al. 2008, Park et al. 
2008, Adam et al. 2009). MiR-335 is also capable of suppressing migration/invasion 
through a different pathway involving the progenitor cell transcription factor SOX4 
and extracellular matrix component Tenascin C (Tavazoie et al. 2008). MiR-34A 
is normally induced by the epigenetic modulator p53, while it can be repressed by 
the cytokine IL-6 and the oncogenic transcription factor STAT3. This event can 
promote EMT-mediated colorectal cancer invasion and metastasis (Rokavec et al. 
2014). MiRNA-466 can reduce prostate cancer tumor growth and bone metastasis 
(Colden et al. 2017). The let-7 family is downregulated in several human cancers, 
which is thought to increase tumorigenicity and metastatic ability in breast cancer 
(Yu, Yao et al. 2007). Interestingly, the mature let-7 can be inhibited by another 
miRNA, miR-107, an event that promotes tumor progression and metastasis (Chen et 
al. 2011). Remarkably, circulating miRNAs may also serve as biomarkers for cancer 
prognosis. A study performed in serum samples from patients with colorectal cancer 
identified increased levels of circulating miR-92a and mir-29a (Huang et al. 2010). 
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Similarly, increased serum levels of miR-141 are observed in prostate cancer patients 
when compared to healthy individuals (Mitchell et al. 2008). The striking involve-
ment of miRNAs in several critical cancer-associated processes makes them highly 
interesting molecules for therapeutic applications. So far, two potential approaches 
for the regulation of miRNA expression have been evaluated for their use in can-
cer treatment. One approach is to introduce antisense RNA (Anti-miRs), which can 
block the function of oncogenic miRNAs, or the re-introduction of a synthetic miR-
NAs to mimic the action of the tumor suppressor miRNAs. The other approach is 
focused on inducing the expression of the miRNAs using drugs. The use of drugs 
implies the modification of the oligonucleotide structure in order to avoid filtration 
by the kidneys and their clearance through the urine (Chan and Wang 2015).
18.2.10  epigeNetic iNactivatioN of dNa repair geNes
Efficient DNA repair is crucial for preventing cancer. Earlier, we discussed how muta-
tions in DNA repair genes could cause inherited cancer syndromes. We also exam-
ined how mutations in the epigenetic machinery contribute to cancer. Additionally, 
DNA repair pathways may be inactivated or decreased in effectiveness by epigenetic 
inactivation mechanisms affecting DNA repair genes. While mutations in the DNA 
repair machinery are quite rare in sporadic cancers, those that present with DNA 
repair deficiencies have one or more epigenetic alterations that reduce or silence the 
expression of the DNA repair genes (Bernstein and Bernstein 2015). DNA methyla-
tion at the promoter region of genes participating in DNA repair pathways including 
DR, BER, NER, HR, NHEJ, and others has been reported in several cancers, sum-
marized in Table 18.3 and discussed below. It can be assumed that the epigenetic 
inactivation of DNA repair genes can result in an increase in genetic instability that 
contributes to tumor progression. On the other hand, diminished DNA repair may 
TABLE 18.3
DNA Repair Genes Methylated in Cancer
DNA Repair 
Pathway Gene Methylated
BER MBD4 (Howard et al. 2009, Peng et al. 2006); TDG (Peng et al. 2006); OGG1 (Guan 
et al. 2008); NEIL1 (Do et al. 2014)
DR MGMT (Herfarth et al. 1999)
NER XPC (Yang et al. 2010); RAD23A (Peng et al. 2005); RAD23B, ERCC1 (Chen et al. 
2010); ERCC4
MMR MLH1 (Guan et al. 2008, Esteller et al. 1998, Wang et al. 2003, Kim et al. 2010, 
Hinrichsen et al. 2014); MSH2 (Wang et al. 2003, Lawes et al. 2005, Hinrichsen et al. 
2014); MSH3 (Kim et al. 2010), MSH6 (Lawes et al. 2005); PMS2 (Hinrichsen et al. 
2014)
HR BRCA1 (Dobrovic and Simpfendorfer 1997, Lee, Tseng et al. 2007)
NHEJ XRCC5 (Lee, Tseng et al. 2007)
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also lead to reduced cell survival in general, and additional events are likely occur-
ring that enable a cell with reduced repair capacity to undergo uncontrolled prolif-
eration instead of cell death (e.g. TP53 pathway inactivation).
18.2.10.1  DR
Epigenetic silencing of the MGMT gene has been broadly reported in solid tumors 
including colon cancer (Herfarth et al. 1999), glioblastoma (Esteller et al. 2000), 
non-small cell lung cancer (Wolf et al. 2001), and gastric cancer (Oue et al. 2001), 
among others. Furthermore, in glioma patients, epigenetic silencing of the MGMT 
gene correlates with better response to alkylating agent treatments when compared 
to patients with tumors with active MGMT (Esteller et al. 2000, Hegi et al. 2005).
18.2.10.2  BER
As discussed previously, in BER, MBD4 and TDG are important enzymes for coun-
teracting the hydrolytic deamination of 5-methylcytosine. Promoter methylation of 
these two DNA repair genes has been observed in various cancer cell lines (Peng et 
al. 2006, Howard et al. 2009). Furthermore, epigenetic silencing of OGG1, involved 
in the repair of 8-oxoguanine, has also been observed in some cancer cell lines 
(Guan et al. 2008).
18.2.10.3  NER
The XPC gene, which encodes for the essential subunit for the damage recognition 
complexes in GGR (Friedberg 2001, Riedl, Hanaoka, and Egly 2003), is silenced 
in bladder cancer through DNA hypermethylation (Yang et al. 2010). In addition, 
RAD23A and ERCC1, two genes that are involved in DNA damage recognition and 
incision, respectively, as part of the NER pathway are also inactivated through DNA 
methylation of their promoter region. The RAD23A gene is methylated in the mul-
tiple myeloma cell line KAS-6/1 (Peng et al. 2005) and ERCC1 is epigenetically 
silenced through DNA methylation is associated with drug resistance in glioma cell 
lines and glioma tumors (Chen et al. 2010).
18.2.10.4  MMR
Approximately 13% of all colorectal cancers present deficiencies in MMR. Among 
the majority of these—particularly in sporadic disease—have loss of MMR due to 
silencing of MLH1 through DNA methylation of the promoter region of the gene 
(Truninger et al. 2005, Kane et al. 1997). Additionally, this gene is epigenetically 
inactivated in other types of cancer, including sporadic endometrial carcinoma 
(Esteller et al. 1998), gastric cancers (Fleisher et al. 1999), ovarian tumors (Gras 
et al. 2001, Zhang, Zhang et al. 2008), oral squamous cell carcinoma (Czerninski 
et al. 2009), neck squamous cell carcinoma (Liu et al. 2002), and acute myeloid 
leukemia (AML) (Seedhouse, Das-Gupta, and Russell 2003). Beyond MLH1, other 
genes that belong to the MMR pathway are also controlled by promoter methylation, 
including MSH2, MSH3, and MSH6. Indeed, MSH2, MSH3 and MSH6 are also DNA 
methylated in colorectal cancer (Lawes et al. 2005, Benachenhou et al. 1998). MSH2 
is also DNA methylated in primary non-small cell lung cancer (Wang and Qin 
2003), oral squamous cell carcinoma (Czerninski et al. 2009), and ovarian cancer 
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(Zhang, Zhang et al. 2008). Interestingly, the methylation frequencies in MLH1 and 
MSH3 were significantly higher in elderly gastric carcinoma patients than in younger 
patients (Kim et al. 2010). Thus, DNA methylation of these genes may have consider-
able importance in cancer development and as a prognostic factor.
18.2.10.5  HR
Mutation of the BRCA1 tumor suppressor gene is an important contributing factor 
in hereditary breast and ovarian cancer. However, BRCA1 mutations have not been 
detected in the sporadic forms of these cancers. Still, BRCA1 mRNA and protein 
levels are reduced in some sporadic breast and ovarian cancers. Aberrant promoter 
methylation of the BRCA1 promoter is correlated with the low mRNA and protein 
levels (Dobrovic and Simpfendorfer 1997). The BRCA1 promoter is also methylated in 
gastric cancer (Bernal et al. 2008), non-small cell lung cancer (Lee, Tseng et al. 2007), 
uterine leiomyosarcoma (Xing et al. 2009), and bladder cancer (Yu, Zhu et al. 2007).
18.2.10.6  NHEJ
While genetic mutation of the genes that regulate NHEJ have not been reported, a defi-
ciency in expression of the Ku80 protein has been observed in melanoma (Korabiowska 
et al. 2002). In addition, low expression of Ku80 was found in 15% of adenocarcinoma 
type and 32% of squamous cell type non-small cell lung cancers, which correlated 
with hypermethylation of the XRCC5 promoter (Lee, Tseng et al. 2007).
18.2.11  epigeNetics iN caNcer stem ceLLs
Cancer stem cells (CSCs) are a rare subpopulation of cells present within tumors 
with the capacity to self-renew and regenerate the whole tumor (Reya et al. 2001). 
While CSCs were first described in myeloid leukemia, they have also been identified 
in solid tumors including breast, prostate, colon, brain, pancreas, liver, ovary, mela-
noma, skin, and head and neck. CSCs are thought to be responsible for sustaining 
tumor growth and metastases. Most importantly, CSCs are more resistant to thera-
peutic agents than the non-stem tumor cells, suggesting that CSCs are responsible for 
tumor relapse. Most of the epigenetic mechanisms with roles in promoting the acqui-
sition of uncontrolled self-renewal previously described in this chapter may contrib-
ute to CSC formation and maintenance. One of the best examples of the relevance 
of DNA methylation in CSC regulation and tumor growth is portrayed in leukemia 
stem cells, where abrogation of Dnmt1 expression blocks leukemia development in a 
mouse model. Furthermore, haploinsufficiency of Dnmt1 results in tumor suppressor 
gene activation, impaired CSC self-renewal and delayed progression of leukemo-
genesis (Trowbridge et al. 2012). Histone methylation also appears to be involved 
in CSC formation and maintenance. The Polycomb group complexes target similar 
sets of CpG-containing genes in embryonic stem cells as in cancer cells, suggesting 
that these genes may be responsible for the emergence of the CSC phenotype during 
tumorigenesis (Schlesinger et al. 2007, Widschwendter et al. 2007, Ohm et al. 2007). 
Further, a knock-in mouse model inducing the expression of EZH2 in hematopoietic 
stem cells was shown to promote myeloid expansion, which indicates a stem cell-
specific EZH2 oncogenic role in myeloid disorders (Herrera-Merchan et al. 2012). 
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Several other studies support the idea that increased EZH2 expression in some tumors 
contributes to the maintenance of a reversible and undifferentiated stem-like pheno-
type in cancer cells and the expansion of breast CSCs (Chang et al. 2011, Burdach 
et al. 2009). Inhibition of other Polycomb proteins including LSD1 and MLL1 has 
also been shown to decrease CSC proliferation potential and tumorigenicity (Wang, 
Lu et al. 2011, Heddleston et al. 2012). Several miRNAs cooperate with Polycomb 
complexes and DNA methylation to regulate the balance between self-renewal and 
differentiation in CSCs (Esquela-Kerscher and Slack 2006; Volinia et al. 2006). Let-7 
is thought to play a critical role in the breast CSC maintenance (Viswanathan et al. 
2009; Yang et al. 2010) and contributes to EZH2 overexpression in prostate cancer 
(Kong et al. 2012). The downregulation of the miR-200 family members is linked to 
proliferation of CSCs and their ability to form tumors (Iliopoulos et al. 2010; Lo et 
al. 2011; Shimono et al. 2009). Further, miR-34a, which is underexpressed in CSCs, 
negatively regulates the tumor initiating capacity of prostate (Liu et al. 2011), pan-
creatic (Ji et al. 2009b), and breast (Yu et al. 2012) CSCs.
18.3  CONCLUSION AND FUTURE PROSPECTS
The ongoing molecular characterization of DNA damage response and repair path-
ways, and how they influence chemo- and radio-resistance, guides the development 
of novel cancer therapeutics. This information is instrumental in developing DNA 
repair inhibitors, the latest effort in creating more targeted anticancer treatments that 
cause less toxicity to normal cells. DNA repair inhibitors are essential in the applica-
tion of synthetic lethal combinations of drugs and genetic deficiencies.
It is interesting to point out that while in most repair pathways there are several 
proteins involved in the repair process, within each DNA repair pathway there are 
specific genes that are preferentially epigenetically silenced. It is yet to be deter-
mined whether this specificity is due to selection of particular repair gene silencing 
events in promoting tumorigenesis or is due to preferential targeting of the DNA 
methylation machinery to specific DNA repair gene promoters (Lahtz and Pfeifer 
2011).
It is also interesting that epigenetic inactivation of DNA repair pathways can lead 
to different clinical outcomes. Reduced repair capacity for alkylated guanines by 
promoter methylation of the MGMT gene provides a therapeutic benefit in patients 
with glioma (Esteller et al. 2000). On the other hand, inactivation of the MMR sys-
tem is associated with resistance of cells to cisplatin treatment (Fink, Zheng et al. 
1997, Fink, Nebel et al. 1997). With the mounting knowledge regarding the epig-
enome of specific cancer types, there is now an opportunity to develop chemotherapy 
regimens tailored to a patient’s DNA repair gene status by incorporating information 
on epigenetic silencing of the relevant genes in the tumor.
Studies during the last decade emphasize the importance of epigenetic mecha-
nism at most stages during cancer development, which given the reversible nature of 
epigenetics, present novel opportunities for therapeutic intervention. The observation 
that genes involved in epigenetic regulation are among the most commonly mutated 
gene families, underscores the importance of further understanding the epigenetic 
mechanisms participating in tumor maintenance and progression. Advances in the 
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field will likely require elucidating how different epigenetic proteins contribute to 
gene-specific gene expression modulation, which would refine our understanding 
of their roles in tumor maintenance. Considering the multiple roles of epigenetics in 
cancer, and the possible interference with normal homeostasis, epigenetic interven-
tions in carcinogenesis still faces many challenges, but also offers groundbreaking 
opportunities to the treatment of these devastating malignancies.
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